MorphoSys, a biotechnology company, agreed to acquire Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company, for $1.7bn. Royalty Pharma will support the acquisition of Constellation. “This transformational acquisition represents a major step forward for MorphoSys as we bolster our position in hematology-oncology. Both pelabresib and CPI-0209 have broad potential and we look forward to unlocking their full benefits for cancer patients. Our existing clinical and commercial expertise is ideally suited to accelerate Constellation’s programs, enabling us to maximize Constellation’s potential and bring these novel therapies to market. With Constellation’s high-potential product candidates, complementary R&D capabilities, and outstanding team, we can further advance our mission in the fight against cancer," Jean-Paul Kress, MorphoSys CEO.